Page 24 - Laboratory Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Like the united states. it only has 6% of the population over 65. it had three-quarters who had been infected, and it has less than a third vaccinated. so we're trying to project against the data that we have. the solid data is on how many cases there would be. where we're hopeful is based on laboratory data. it's based on t-cell studies. so we're hopeful that it will be less lethal, less virulent. we know it will be more transmissible, and those are the two things we have to juggle as we go through a holiday season. >> you have been writing about this, fighting covid in "the wall street journ...

You can — roll—out, is occurring in red and you can see _ roll—out, is occurring in red and you can see it is going up very rapidly— you can see it is going up very rapidly and accelerating and that will continue to happen over the next _ will continue to happen over the next period of time. next slide, please — next period of time. next slide, please. when i showed the side at the last— please. when i showed the side at the last session people said they wanted _ the last session people said they wanted a — the last session people said they wanted a bit more time on it and i want...

To have mild disease. that's not surprising. my suspicion is that there are probably many more cases. we just haven't identified them. so as we do, i think we will learn more about whether unvaccinated people who are getting infected, whether they're also having mild disease. obviously, we all hope it does. my expectation right now is for the unvaccinated, it will be like delta, but for the vaccinated who have breakthroughs,tail do better. >> dr. fauci says based off of tests so far, at least, it looks like there's very good vaccine efficacy against this variant. but what will you be looking f...

Fauci. we're discussing the news from pfizer as well as the surge in cases from the u.s. from the delta variant. welcome, thank you for being with us. >> let's begin with your action that this is a preliminary study from pfizer, it still has to be gone over by all of you, but what are you, the scientists here in the u.s., thinking about this? first, it's a laboratory data that would project what you might see clinically. so the proof will be what they think, but it projects accurately what you would see and one of the things that were a concern is would it be protected by the antibodies, and t...

With the new omicron variant the initial study shows that for people with two doses of the mrna vaccine, the protection against infection -- at least laboratory data, we don't have clinical data yet -- diminishes significantly. however, as people from pfizer pointed out, when you get that third shot boost, it dramatically increases the level of laboratory projected protection. in other words, if you look at the level of antibodies and very likely other immune parameters, that you still stay within the level of protection, which is really very encouraging news because everyone obviously is conc...